• Cancel
    Date：2020-08
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=526

    Suzhou Connect Biopharmaceuticals Co., Ltd. (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating molecules, today announced the completion of its USD 115 million Series C financing led by RA Capital Management. New investors Lilly Asia Ventures, Boxer Capital, and HBM Healthcare Investments also joined the round along with existing investor Qiming Venture Partners. The Company also announced that, in conjunction with the financing, Derek DiRocco, Ph.D., Principal at RA Capital Management, is joining Connect Biopharma’s Board of Directors. The Company plans to use the proceeds of the Series C financing to support the ongoing Phase 2 clinical trial for CBP-201 in adult patients with moderate-to-severe atopic dermatitis (AD) and the ongoing Phase 2 trials of CBP-307 in patients with moderate-to-severe ulcerative colitis (UC). The Company also aims to expand the CBP-201 clinical development program into additional indications, and manufacture clinical material to support future Phase 3 trials of CBP-201 and CBP-307. The Company also expects to use a portion of the proceeds to advance additional preclinical programs into clinical development, including CBP-174, a small molecule in development for the treatment of pruritus.

  • Cancel
    Date：2020-08
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=519

    Guangzhou Weiyuan (Vision Medicals) Gene Technology Co., Ltd. (hereinafter referred to as “Vision Medicals” or the “Company”), a leader in the infection precision medicine industry, recently announced the completion of a Series B financing round of several hundred million RMB. This round of financing was led by CDH Investment, with participation from CICC Qichen and existing shareholders, Volcanics Venture and Cash Capital. This round of financing will primarily be used for funding product R&D, establishing a clinical testing network, driving product registration efforts, constructing manufacturing facilities, improving clinical services, and increasing brand marketing. CEC Capital Group served as the exclusive financial advisor of Vision Medicals in this transaction.

  • Cancel
    Date：2020-07
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=462

    Shanghai, 27 July 2020— Shanghai Haihe Pharmaceutical Co., Ltd (hereinafter referred to as "Haihe Pharmaceutical"), a leading biotech company focuses on the discovery and development of innovative drugs for cancer, announced today that it has closed ￥1.20 Billion Series B Financing. This round of financing was led by Warburg Pincus, joined by CMBI, Legend Capital, CICC Capital, Chaos Investment, ALAN Asset Management, Ruihua Investment, SSC and Series A investors BioTrack Capital, Yingke PE, Atlas Capital, CSPC and affiliated parties. The company intends to use the funds to advance its pipeline, which includes the ongoing R&D and commercialization of multiple anti-tumor innovative drugs worldwide. CEC Capital served as the exclusive financial adviser to Haihe Pharmaceutical during this round of financing.

  • Cancel
    Date：2020-07
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=435

    CF PharmTech, Inc., a pharmaceutical company with a vision to provide quality and affordable respiratory drug products globally, announced it has raised a $90 million Series E investment led by New Alliance Capital. The investment included participation f

  • Cancel
    Date：2020-06

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2020-06

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2020-05

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2020-05

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2020-03

    CEC Capital Served as Financial Advisor